The aim of the study was to determine the efficacy and @entity137 of pemetrexed plus rituximab in @entity1 with @entity149 , who had undergone treatment with @entity2101 ( @entity2101 ) @entity1499 -based regimens. @entity1 who had failed @entity2101 @entity1499 -based regimens treatment had ECOG performance status ranging from 0 to 2. Twenty-seven @entity1 received pemetrexed plus rituximab as second-line treatment. @entity2408 375  mg/m(2) was administered on day 0 and pemetrexed 500  mg/m(2) was administered on day 1 every 3  weeks. Six @entity1 (22.2  %) experienced CR, 11 @entity1 (40.7  %) had PR, eight @entity1 (29.6  %) had @entity168 , and two @entity1 had @entity1726 . The response rate was 62.9  %. The median time to progression (PFS) was 6.9  months (95  % CI, 5.6-8.3), and the median overall survival was 11.2  months (95  % CI, 9.1-13.4). In the subgroup analysis, PFS had a significant difference among the low level of serum @entity10017 and high level of serum @entity10017 . PFS was 9.0 (95  % CI, 6.3-11.6) and 5.7  months (95  % CI, 4.6-6.9, log rank  =  0.015), respectively. None of the @entity1 experienced grade 4 @entity137 . A regimen of pemetrexed combined with rituximab is marginally effective and well tolerated in @entity1 with PCNSL who had failed @entity2101 @entity1499 -based regimens first-line treatment.

Pemetrexed plus rituximab as second-line treatment for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity168 :: ('MESH:D029461', 'Disease') :: ['SD'] @entity149 :: ('MESH:D002493', 'Disease') :: ['primary central nervous system lymphoma'] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD'] @entity10017 :: ('406991', 'Gene') :: ['miR-21'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['HD', 'high-dose'] @entity2408 :: ('CHEBI:64357', 'Chemical') :: ['Rituximab'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity149 :: (MESH:D002493,Disease) :: ['primary central nervous system lymphoma']
